Acceleron resurrects blockbuster hopes for sotatercept with positive PhII — and shares rocket up
Acceleron $XLRN says that its first major trial readout of 2020 is a success.
In a Phase II study of 106 patients with pulmonary arterial hypertension (PAH), Acceleron’s experimental drug sotatercept hit its primary endpoint: a significant reduction in pulmonary vascular resistance. The drug also met three different secondary endpoints, including the 6-minute walking test.
“We’re thrilled to report such positive topline results from the PULSAR trial,” Acceleron CEO Habib Dable said in a statement. The company said in a conference call they plan on discussing a Phase III trial design with regulators.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.